Background: In patients with heart failure and reduced left ventricular ejection fraction,
angiotensin receptor blockers have been found to reduce mortality and morbidity and to …

Background: Heart failure places a burden on patients and health care systems worldwide.
Although the advent of angiotensin-converting enzyme (ACE) inhibitors markedly improved …

The role of angiotensin receptor blockers (ARBs) in patients with left ventricular dysfunction
has changed after the VALIANT and CHARM trials. CHARM proved that candesartan is a …

Homeostasis in the cardiovascular system is maintained by physiological functions of the
Renin Angiotensin Aldosterone System (RAAS). In pathophysiological conditions, over …

Heart failure which occurs due to various causes including primarily coronary artery
diseases and hypertension is a syndrome with complex physiopathology and clinic that can …

Background: The Valsartan Heart Failure Trial (Val-HeFT) is the first large-scale
randomized, multinational clinical study to assess the efficacy and safety of valsartan, an …

Angiotensin receptor blockers (ARBs) have a pharmacological role in the treatment of heart
failure through their blockade of the effects of angiotensin II. ARBs, however, lack the …

Heart failure is a common and disabling condition with a dismal prognosis. Inhibition of the
renin-angiotensin-aldosterone system (RAAS) with angiotensin converting enzyme (ACE) …

Background: Although current therapies have improved heart failure (HF) outcome,
hospitalizations continue at high rates. The Valsartan Heart Failure Trial (Val-HeFT) showed …

Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce morbidity and
mortality in patients with heart failure due to systolic left ventricular dysfunction and are …